^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAY 2965501

    i
    Other names: BAY 2965501, BAY2965501, BAY-2965501
    Associations

    News

    Trials
    Company:
    Bayer, German Cancer Research Center
    Drug class:
    DGKZ inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=284, Active, not recruiting, Bayer | Trial completion date: Jun 2027 --> Sep 2027
    Trial completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • BAY 2965501
    8ms
    A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=284, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • BAY 2965501
    12ms
    A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=284, Recruiting, Bayer | Trial completion date: Aug 2026 --> Jun 2027 | Trial primary completion date: Aug 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • BAY 2965501
    over2years
    A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=284, Recruiting, Bayer | N=179 --> 284
    Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    Keytruda (pembrolizumab) • BAY 2965501
    over3years
    A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=179, Recruiting, Bayer
    New P1 trial • Metastases
    |
    IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    BAY 2965501